Fatma Chaker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fatma Chaker has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ibtissem Oueslati
Department of endocrinology, La Rabta University Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia
5 shared publications - Melika Chihaoui
Department of endocrinology, La Rabta University Hospital, Faculty of Medicine of Tunis, University of Tunis-El Manar, Tunis, Tunisia
5 shared publications - Meriem Yazidi
Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
5 shared publications Nadia Khessairi
Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
3 shared publicationsChayma Belhadjsliman
Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
2 shared publicationsElyes Kamoun
Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia
2 shared publications
Latest Publications
- 18 October 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (2) , 359-367
Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring
Background Patients with primary adrenal insufficiency (PAI) are at increased risk of hypoglycaemia and dehydration. We aimed to evaluate the risk of complications, particularly hypoglycaemia, associated with Ramadan fasting (RF) in patients with PAI, using continuous glucose monitoring (CGM). Methods In this prospective, randomised, crossover, case-control study, we evaluated the prevalence of complications using clinical, biological and CGM data during RF and non-fasting days in 30 patients with PAI. All participants were treated with hydrocortisone and fludrocortisone and received a therapeutic education. Results 27 women and 3 men, mean age: 44.8±9.2 years, median duration of PAI: 7 years (4-10.5). Median daily doses were 20 mg of hydrocortisone and 50 µg of fludrocortisone. The prevalence of complications was 67% during RF and 23% outside RF (p = 0.001). Eleven patients (37%) broke the fast due to the occurrence of a complication. Signs of hypoglycaemia were reported by 37% of the patients during RF and 3% outside fasting (p = 0.002). Mean interstitial glucose levels were lower during fasting than outside fasting. The prevalence of CGM-detected hypoglycaemia (71% vs. 63%, p = 1.000), time spent below 3.9 and 3.0 mmol/l, and blood pressure levels were not different between RF and non-fasting days. Urea levels increased during RF but remained within normal limits. Conclusion Complications were frequent during RF in patients with PAI. Hypoglycaemia was frequent both during and outside RF. Registered on Clinical Trials on February 28th, 2024, under the identifier NCT06299020.
- 18 October 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (2) , 359-367
Hypoglycaemia and other risks of ramadan fasting in patients with primary adrenal insufficiency: A prospective controlled trial using 24-hour glucose monitoring
Background Patients with primary adrenal insufficiency (PAI) are at increased risk of hypoglycaemia and dehydration. We aimed to evaluate the risk of complications, particularly hypoglycaemia, associated with Ramadan fasting (RF) in patients with PAI, using continuous glucose monitoring (CGM). Methods In this prospective, randomised, crossover, case-control study, we evaluated the prevalence of complications using clinical, biological and CGM data during RF and non-fasting days in 30 patients with PAI. All participants were treated with hydrocortisone and fludrocortisone and received a therapeutic education. Results 27 women and 3 men, mean age: 44.8±9.2 years, median duration of PAI: 7 years (4-10.5). Median daily doses were 20 mg of hydrocortisone and 50 µg of fludrocortisone. The prevalence of complications was 67% during RF and 23% outside RF (p = 0.001). Eleven patients (37%) broke the fast due to the occurrence of a complication. Signs of hypoglycaemia were reported by 37% of the patients during RF and 3% outside fasting (p = 0.002). Mean interstitial glucose levels were lower during fasting than outside fasting. The prevalence of CGM-detected hypoglycaemia (71% vs. 63%, p = 1.000), time spent below 3.9 and 3.0 mmol/l, and blood pressure levels were not different between RF and non-fasting days. Urea levels increased during RF but remained within normal limits. Conclusion Complications were frequent during RF in patients with PAI. Hypoglycaemia was frequent both during and outside RF. Registered on Clinical Trials on February 28th, 2024, under the identifier NCT06299020.
- Open Access
- 6 November 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (11) , e6543
Thyroid hormone resistance syndrome caused by a novel mutation in the thyroid hormone receptor‐beta gene ( THRB , GLU457LYS ) treated with methimazole
A 15‐year‐old girl presented with hyperactivity and behavior disorders. She had tachycardia and no goiter. Thyroid hormones were high and TSH normal. A novel mutation GLU457LYS in THRB gene was observed. Methimazole and propranolol improved clinical symptoms but increased TSH level.
- 6 November 2022
- Published by Wiley in Clinical Case Reports
- Vol. 10 (11) , e6543
Open AccessThyroid hormone resistance syndrome caused by a novel mutation in the thyroid hormone receptor‐beta gene ( THRB , GLU457LYS ) treated with methimazole
A 15‐year‐old girl presented with hyperactivity and behavior disorders. She had tachycardia and no goiter. Thyroid hormones were high and TSH normal. A novel mutation GLU457LYS in THRB gene was observed. Methimazole and propranolol improved clinical symptoms but increased TSH level.
- Open Access
- 23 March 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 222-228
The remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus: prevalence, predicting factors and glycemic control during follow-up
Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between [...] ABSTRACT Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between
- 23 March 2022
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 66 (2) , 222-228
Open AccessThe remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus: prevalence, predicting factors and glycemic control during follow-up
Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between [...] ABSTRACT Objective: There is little data about the remission phase in adolescents and young adults with newly diagnosed type 1 diabetes mellitus (T1D). The aims of this study were to determine the prevalence of remission and its predicting factors among adolescents and young adults with newly diagnosed T1D and to assess the association between remission and long-term glycemic control in this population. Subjects and methods: This is a longitudinal and retrospective study including 128 type 1 diabetic patients aged between